UNSPSC 51383103: Quinupramine

This classification denotes a dibenzazepine and quinuclidine with the molecular formula C21H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29O61HFF4L, chemically known as 10,11-dihydro-5-(3-quinuclidinyl)-5h-dibenz(b,f)azepine but generally known as quinupramine, which bears US NIH Compound Identifier 93154. European Medicines Agency schedules Quinupramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10225MIG.

UNSPSC 51383103 Quinupramine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The three recent opportunities tagged to this code involve naloxone distribution, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and OTC products — none of which center on quinupramine specifically. The naloxone and drug deactivation systems procurement from Seminole County, Florida and the generic pharmaceuticals cooperative purchasing agreements through MMCAP represent actual state and local buying patterns, but they do not reflect demand for quinupramine as a distinct product line. The Texas HHS Commission RFI on therapeutic pharmacy initiatives is exploratory market research rather than a product procurement.

Seminole County posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: date discrepancy in source), requiring quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The MMCAP cooperative purchasing vehicle, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP due March 26, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with products to be supplied through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson). The Texas HHS Commission posted an RFI on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Because the code shows no substantive recent solicitation activity for quinupramine itself, pursuit under this code should be deferred until state and local demand emerges.